Real-world risk assessment, outcomes and adoption of novel drugs in CLL patients: insights from US databases
Real-world risk assessment, outcomes and adoptio
Promising novel approaches in various B-cell malignancies
Promising novel approaches in various B-cell mal
Paolo Ghia
ASH 2021 - Paolo Ghia Paolo Ghia highlights what
Alessandra Tedeschi
ASH 2021 - Alessandra Tedeschi Alessandra Tedesch
Jennifer Woyach
ASH 2021 - Jennifer A. Woyach Jennifer A. Woyach
Constantine Tam
ASH 2021 - Constantine Tam Constantine Tam gives
Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulinemia
Phase II data on novel BTK inhibitors for patien
Marginal zone lymphoma: PI3Kδ inhibition and beyond
Marginal zone lymphoma: PI3Kδ inhibition and bey
Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries
Mantle cell lymphoma: refining clinical outcomes
Management of patients with relapsed/refractory CLL: what is new?
Management of patients with relapsed/refractory
